March 10, 2015Cellectar Biosciences to Present at 27th Annual Roth Conference Peer-Reviewed Glioma Surgery Study With Cellectar Biosciences Fluorescence Cancer-Targeting Agents Chosen for the Cover of Neurosurgery
Cellectar’s product candidates are built on a novel, cancer and cancer stem cell-targeting delivery and retention platform of optimized phospholipid ether analogs (PLEs). We have shown that PLEs become trapped in malignant tumor cell membranes because tumor cells cannot metabolize and eliminate them.
The Annual Meeting of Stockholders of Cellectar Biosciences, Inc. will be held on Thursday, May 28, 2015 at 10:00 A.M., local time, at its headquarters at 3301 Agriculture Drive, Madison, WI 53716
CLRB 2014 Amended Annual Report(pdf)
Proxy Statement (pdf)